Skyland PIMS® version 4.1 introduces additional features to help life science companies centralize and analyze drug process and product data across teams, sites, and manufacturing partners.
Skyland Analytics, a leader in cloud-based data analytics and data management software solutions for clinical and commercial-stage bio/pharma developers and manufacturers, announced the latest release of Skyland PIMS process information management and data collaboration platform. PIMS™ 4.1 delivers enhanced analytic and visualization functionality and also expands the statistical analytics within the PIMS Stability™ module. This news follows an announcement earlier this year that Skyland Analytics’ market share has climbed as drug and COVID-19 vaccine developers look to accelerate time-to-market through digital transformation.
Recommended ITech News: Businesses Invest in Artificial Intelligence & Machine Learning to Expand Digital Business Plans
“This latest release of PIMS equips users with more ways to drill into product and process data, accelerate investigations, and analyze the stability and quality of therapeutic products,” said Joe Ruth, Chief Software Architect at Skyland Analytics. “We have accelerated customer adoption because the industry knows our deep expertise in this space and commitment to continuous product enhancements, including significant additional functionality in the works with our forthcoming PIMS release later this year,” he commented.
The latest PIMS release includes these new product features:
- Stability pooling and d***** analytics
- Correlation and regression analytics; discrete line plots; derived parameter capabilities, including calculations across unit operations
- New Chart Boards allowing comparative analysis of products, sites, and partners
- Genealogy of raw materials
Recommended ITech News: iboss Expands CASB Functionality and Security Abilities on iboss Cloud Platform
Watch a video presentation now highlighting new Skyland PIMS 4.1 features and value.
Ideally suited for a wide range of bio/pharma products – small molecules, biologics, and cell and gene therapies alike – Skyland PIMS establishes a digital data spine early in the product life cycle which drives higher data integrity and product quality while accelerating tech transfer and commercialization. In a recent announcement, Skyland Analytics reported that it has seen increased adoption of Skyland PIMS as organizations look for data systems that can be deployed rapidly to support accelerated drug development and manufacturing programs.
Recommended ITech News: Steelcase Teams up With Kontrol Technologies to Provide Air Quality Monitoring and Viral Detection Technology
